About RCCS, Inc.
The Research Center for Clinical Studies, Inc. (RCCS) is a clinical research organization located in East Norwalk, Connecticut. The organization conducts Phase II-IV federally funded and Food and Drug Administration (FDA)-approved pharmaceutical-sponsored clinical trials designed to evaluate the safety and efficacy of investigational therapies. The Center provides research trials that are focused on neuropsychiatric disorders, including Alzheimer’s disease and other forms of dementia, depression, schizophrenia, bipolar disorder, and other related conditions.
Since its establishment in 2004, RCCS has provided patients throughout Connecticut, New York, and New Jersey with compassionate, high-quality, no-cost study-related care. It also offers essential support services, including memory testing, pre-screening evaluations and medical consultations to assess eligibility and participation in appropriate clinical studies. Through its collaborations with affiliated hospitals and medical professionals, RCCS ensures access to advanced diagnostic tools and comprehensive study-related care. Its contributions to clinical research are particularly notable in the development of newer and more effective treatments for Alzheimer’s disease and other neuropsychiatric conditions thereby supporting the broader medical community’s efforts to improve patient outcomes and expand therapeutic options.
Since its establishment in 2004, RCCS has provided patients throughout Connecticut, New York, and New Jersey with compassionate, high-quality, no-cost study-related care. It also offers essential support services, including memory testing, pre-screening evaluations and medical consultations to assess eligibility and participation in appropriate clinical studies. Through its collaborations with affiliated hospitals and medical professionals, RCCS ensures access to advanced diagnostic tools and comprehensive study-related care. Its contributions to clinical research are particularly notable in the development of newer and more effective treatments for Alzheimer’s disease and other neuropsychiatric conditions thereby supporting the broader medical community’s efforts to improve patient outcomes and expand therapeutic options.
Our Management Team
Danilo de la Peña, M.D.
Executive Director
Bart A. Sloan, M.D.
Principal Investigator
Aries A. Gee
Site Manager
Executive Director
Bart A. Sloan, M.D.
Principal Investigator
Aries A. Gee
Site Manager